| Name | Title | Contact Details |
|---|
TRIMEDX is a technology-enabled, clinical asset management company, anchored on a strong foundation of clinical engineering, exclusively serving the healthcare community. As the largest independent technology-enabled clinical asset management company in the U.S., TRIMEDX provides strategic planning for - and management of - clinical assets to drive reductions in operational expenses, free up capital for new strategic initiatives, and deliver improved safety and cyber protection. Headquartered in Indianapolis, Indiana, TRIMEDX was built by providers, for providers, and leverages a history of expert clinical engineering to manage over $30 billion in clinical assets across thousands of locations. Our programs include flexible, yet comprehensive management of all patient-based technology, including biomedical, imaging, laboratory, and specialty equipment. Key features of our programs include: • Client Experience Center • Parts and Service Procurement Center • Regulatory Compliance Team • Computerized Maintenance Management System • Equipment Lifecycle Management In September of 2012, TRIMEDX was recognized by Modern Healthcare Magazine as the #1 Clinical Equipment Maintenance Contractor.
Key Benefit Administrators is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Indianapolis, IN. To find more information about Key Benefit Administrators, please visit www.keybenefit.com
MiCardia Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marquette General Health System is a Marquette, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic